New Antimicrobials: For the Present and the Future

Ignatius Fong is the Editor of Springer's Emerging Infectious Diseases of the 21^st Century series. He has served as Chief Editor for six books and the sole author for another six books published in the series. He completed his residency training in Internal Medicine at the University of Toronto and as a Fellow in Infectious Diseases at the University of Washington, Seattle. Dr. Fong has published studies concerning a variety of infectious diseases that include therapeutics and pharmacology of antibiotics, AIDS and the treatment of opportunistic infections, mechanistic and treatment studies of mucosal candidiasis, and pathogenic studies on infection and induction of atherosclerosis in animal models. He was Chief of Infectious Diseases at St. Michael's Hospital (Toronto) for 34 years; he is still on staff in Infectious Diseases and is a Professor of Medicine, Department of Medicine at the University of Toronto, Canada.

1. Antimicrobial Resistance: A crisis in the making.-  2: New Cephalosporins: 5^th and 6^th generations.- 3: New beta-lactam-beta-lactamase inhibitor combinations.- 4: New Glycopeptides: Televancin, dalbavancin and oritavancin.- 5: A new fluoroquinolone-Delafloxacin.- 6: New Oxazolininone---Tedizolid.- 7: New Tetracyclines: Eravacycline and Omadacycline.- 8: Pleuromutilin: A new class of antibiotic: Lefamulin.- 9: New anti-tuberculous drugs: Bedaquiline, Delamanid and Pretomanid.- 10: New systemic antifungal: Isavuconazole.- 11: Newly approved anti-parasitic drugs for malaria, fascioliasis, onchocerciasis, Chagas disease and African trypanosomiasis.-  12:New antiretroviral agents for HIV infection.- 13: New Antiviral agents for cytomegalovirus diseases.- 14: New antiviral agent for influenza: Baloxavir.- 15: Direct antiviral agents for hepatitis C.- 16: Antiviral drugs for SARS-CoV-2 and COVID-19.- 17: New promising antimicrobials in development and novel approaches for treatment of infections.-